RhumbLine Advisers’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-56,322
| Closed | -$273K | – | 3174 |
|
|
2020
Q1 | $273K | Hold |
56,322
| – | – | ﹤0.01% | 2450 |
|
|
2019
Q4 | $599K | Buy |
56,322
+1,924
| +4% | +$19.1K | ﹤0.01% | 2290 |
|
|
2019
Q3 | $566K | Buy |
54,398
+1,945
| +4% | +$25.4K | ﹤0.01% | 2268 |
|
|
2019
Q2 | $804K | Buy |
52,453
+3,269
| +7% | +$47.3K | ﹤0.01% | 2155 |
|
|
2019
Q1 | $632K | Buy |
49,184
+12,046
| +32% | +$136K | ﹤0.01% | 2228 |
|
|
2018
Q4 | $353K | Buy |
37,138
+11,911
| +47% | +$154K | ﹤0.01% | 2452 |
|
|
2018
Q3 | $419K | Sell |
25,227
-13,561
| -35% | -$217K | ﹤0.01% | 2347 |
|
|
2018
Q2 | $623K | Buy |
38,788
+12,732
| +49% | +$227K | ﹤0.01% | 2216 |
|
|
2018
Q1 | $399K | Buy |
26,056
+2,915
| +13% | +$45.4K | ﹤0.01% | 2303 |
|
|
2017
Q4 | $361K | Sell |
23,141
-4,507
| -16% | -$60.3K | ﹤0.01% | 2373 |
|
|
2017
Q3 | $307K | Buy |
27,648
+290
| +1% | +$2.73K | ﹤0.01% | 2546 |
|
|
2017
Q2 | $252K | Buy |
27,358
+4,280
| +19% | +$35.7K | ﹤0.01% | 2644 |
|
|
2017
Q1 | $197K | Buy |
23,078
+3,847
| +20% | +$35.1K | ﹤0.01% | 2654 |
|
|
2016
Q4 | $206K | Sell |
19,231
-5,876
| -23% | -$71.1K | ﹤0.01% | 2659 |
|
|
2016
Q3 | $272K | Sell |
25,107
-1,153
| -4% | -$9.38K | ﹤0.01% | 2533 |
|
|
2016
Q2 | $178K | Buy |
26,260
+4,538
| +21% | +$28.6K | ﹤0.01% | 2799 |
|
|
2016
Q1 | $101K | Buy |
21,722
+2,125
| +11% | +$10.4K | ﹤0.01% | 2893 |
|
|
2015
Q4 | $124K | Buy |
19,597
+395
| +2% | +$3.21K | ﹤0.01% | 2922 |
|
|
2015
Q3 | $170K | Buy |
19,202
+984
| +5% | +$10.3K | ﹤0.01% | 2845 |
|
|
2015
Q2 | $214K | Buy |
18,218
+4,620
| +34% | +$64.1K | ﹤0.01% | 2859 |
|
|
2015
Q1 | $197K | Buy |
+13,598
| New | +$208K | ﹤0.01% | 2838 |
|
|
2013
Q4 | – | Sell |
-8,359
| Closed | -$379K | – | 3026 |
|
|
2013
Q3 | $379K | Buy |
+8,359
| New | +$273K | ﹤0.01% | 2383 |
|
RhumbLine Advisers's STML Position: Q2 2020 in Review
RhumbLine Advisers sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 56,322 shares — an estimated $273K sold.
RhumbLine Advisers first reported a position in STML in Q3 2013 and held it in 22 quarters. The position peaked at $804K in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- RhumbLine Advisers reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- RhumbLine Advisers sold 56,322 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $273K.
- RhumbLine Advisers first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 22 quarters.
- RhumbLine Advisers's Stemline Therapeutics, Inc. position peaked at $804K in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.